Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 701–800 of 1,002
Barbarot, S., Wollenberg, A., Silverberg, J. I., Deleuran, M. S., Pellacani, G., Armario-Hita, J. C., Chen, Z., Shumel, B. S., Eckert, L., Gadkari, A., et al. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1750550 · Cited by 33
“Patients in these trials received dupilumab monotherapy (300mg weekly [qw] or every 2weeks [q2w]; LIBERTY AD SOLO 1 [NCT02277743] and LIBERTY AD SOLO 2 [NCT02277769], data pooled in this analysis) (33) or dupilumab with concomitant TCS (300mg qw or q2w; LIBERTY AD CAF E [NCT02755649](34) and LIBERTY AD CHRONOS [NCT022…”
BackgroundSelf-citationYamamoto, Y., Otsuka, A., Nakashima, C., Ishida, Y., Honda, T., Egawa, G., Amano, W., Usui, K., Hamada, Y., Wada, M., et al. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.12.008 · Cited by 26
Psychosocial Consequences of Hand Eczema—A Prospective Cross-Sectional Study
Zalewski, A., Krajewski, P. K., & Szepietowski, J. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175741 · Cited by 27
“A reduction in depressive and anxiety symptoms (measured with HADS) was presented in two randomized placebo-controlled studies on dupilumab (a monoclonal antibody binding to IL-4/IL-13 receptors), which may link inflammation and mood disorders in the AD patient population [53,54].”
MethodTrave, I., Salvi, I., Burlando, M., Cozzani, E., & Parodi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196291 · Cited by 26
“The patient experienced rapid improvement in his However, after 4 weeks, he developed PsO plaques on his arms and neck associated with erythema and the scaling of the face and scalp with a Psoriasis Area and Severity Index (PASI) score of 2.5 (Figure 1a).”
BackgroundInfluentialInnate Type-2 Cytokines: From Immune Regulation to Therapeutic Targets
Kim, H. Y., Jeong, D., Kim, J. H., & Chung, D. H. (2024) · Immune Network · doi:10.4110/in.2024.24.e6 · Cited by 27
“Dupilumab also shows effectiveness in other type-2 immune diseases, including allergic rhinitis (96), nasal polyposis (97), and atopic eczema (98).”
BackgroundSodium Intake and Atopic Dermatitis
Chiang, B. M., Ye, M., Chattopadhyay, A., Halezeroğlu, Y., Blarigan, E. L. V., & Abuabara, K. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.1544 · Cited by 29
European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
Weißhaar, E., Müller, S., Szepietowski, J. C., Dalgard, F. J., Garcovich, S., Kupfer, J. P., Giménez‐Arnau, A. M., Lambert, J. R., Mettang, T., Misery, L., et al. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.44220 · Cited by 38
Immunomodulating Agents as Antipruritics
Erickson, S. P., Nahmias, Z. P., Rosman, I. S., & Kim, B. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.014 · Cited by 29
Fukuda, K., Ishida, W., Kishimoto, T., & Fukushima, A. (2019) · Allergology International · doi:10.1016/j.alit.2018.12.012 · Cited by 26
Cosmi, L., Maggi, L., Mazzoni, A., Liotta, F., & Annunziato, F. (2019) · European Journal of Immunology · doi:10.1002/eji.201948156 · Cited by 29
Kreeshan, F. C., Al‐Janabi, A., Warren, R. B., & Hunter, H. J. A. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00469-6 · Cited by 32
IgE in the pathophysiology and therapy of food allergy
Michelet, M., Balbino, B., Guilleminault, L., & Reber, L. L. (2021) · European Journal of Immunology · doi:10.1002/eji.202048833 · Cited by 32
Maintz, L., Bieber, T. R. M., Bissonnette, R., & Jack, C. S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.02.027 · Cited by 29
Self-citationTauber, M., Wang, F., Kim, B., & Gaudenzio, N. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.03.012 · Cited by 29
Miyano, T., Irvine, A. D., & Tanaka, R. J. (2021) · Allergy · doi:10.1111/all.14870 · Cited by 30
The pruritogenic role of the type 2 immune response in diseases associated with chronic itch
Ingrasci, G., Lipman, Z. M., Hawash, A. A., Girolomoni, G., & Yosipovitch, G. (2021) · Experimental Dermatology · doi:10.1111/exd.14401 · Cited by 30
Silverberg, J. I., Simpson, E. L., Armstrong, A. W., de Bruin-Weller, M. S., Irvine, A. D., & Reich, K. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00639-y · Cited by 26
Self-citationTakeoka, S., Kamata, M., Yokoi, I., Takehara, A., & Tada, Y. (2021) · Acta Dermato Venereologica · doi:10.2340/actadv.v101.545 · Cited by 26
“Society for Publication of Acta Dermato-Venereologica Dupilumab, a monoclonal antibody targeting interleukin-4 receptor α, demonstrated high efficacy and effectiveness for atopic dermatitis (AD) with tolerable safety in clinical trials (1) and real-world data (2, 3).”
BackgroundCather, J. C., Young, M. S., DiRuggiero, D., Tofte, S. J., Williams, L., & Gonzalez, T. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00778-y · Cited by 30
“PHASE 3 TRIALS OF DUPILUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE AD Phase 3 Trials of Dupilumab in Adults with Moderate-to-Severe AD Four major phase 3 clinical trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD SOLO-CONTINUE, and LIBERTY AD CHRONOS) were conducted worldwide in adults with moderate-to-severe…”
BackgroundBlauvelt, A., Wollenberg, A., Eichenfield, L. F., Zhang, H., Sierka, D., Khokhar, F. A., Vakil, J., Shabbir, A., Marco, A. R., & Cyr, S. L. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02322-y · Cited by 26
Self-citationCaffarelli, C., Giannetti, A., Giannì, G., & Ricci, G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1214963 · Cited by 27
Dust mite induces multiple polar T cell axes in human skin
Malik, K., Ungar, B., Garcet, S., Dutt, R., Dickstein, D. R., Zheng, X., Xu, H., Estrada, Y. D., Suárez‐Fariñas, M., Shemer, A., et al. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.13040 · Cited by 30
“Conclusion: While HDM caused significant Th2 skewing, it also illustrated differ- ences in Th2 induction and barrier defects; thus, HDM APT does not fully simulate AD.”
BackgroundInfluentialSelf-citationWerfel, T. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000477 · Cited by 29
Schlösser, A. R., Nijman, L., Schappin, R., Nijsten, T. E. C., & Hijnen, D. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.41504 · Cited by 30
Zhao, Y. P., Gooderham, M., Yang, B., Wu, J., Wu, L., Loo, W. J., Toth, D. P., Sauder, M. B., Li, J., Chen, A., et al. (2025) · JAMA Dermatology · doi:10.1001/jamadermatol.2025.0982 · Cited by 27
Dupilumab for the Treatment of Atopic Dermatitis
Ferreira, S., & Torres, T. R. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2018.02.019 · Cited by 30
Dupilumab in the Treatment of Asthma
Grey, A., & Katelaris, C. H. (2019) · Immunotherapy · doi:10.2217/imt-2019-0008 · Cited by 26
Review of biologics in allergic contact dermatitis
Bhatia, J., Sarin, A., Wollina, U., Lotti, T., Navarini, A. A., Mueller, S. M., Grabbe, S., Saloga, J., Rokni, G. R., & Goldust, M. (2020) · Contact Dermatitis · doi:10.1111/cod.13584 · Cited by 25
TH cell diversity and response to dupilumab in patients with atopic dermatitis
Trichot, C., Faucheux, L., Karpf, L., Grandclaudon, M., Pattarini, L., Bagot, M., Mahevas, T., Jachiet, M., Saussine, A., Bouaziz, J., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.037 · Cited by 25
A review of nephrotic syndrome and atopic diseases in children
Zheng, Y., Hou, L., Wang, X.-L., Zhao, C., & Du, Y. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-665 · Cited by 27
“In addition, it has been recently found that monoclonal anti-IgE antibody omalizumab (64), human-mouse chimeric monoclonal anti-CD20 antibody rituximab, and anti-IL-4/ IL-13 antibody dupilumab (65) can also achieve a good therapeutic effect.”
BackgroundSafety of dupilumab in patients with atopic dermatitis: expert opinion
Francuzik, W., Alexiou, A., & Worm, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1939673 · Cited by 28
“Clinical phase II and III studies reported increased rates of the onset of moderate to severe conjunctivitis and keratoconjunctivitis in patients receiving dupilumab [6].”
BackgroundSelf-citationAhn, J., Lee, D. H., Na, C. H., Shim, D. H., Choi, Y. S., Jung, H. J., & Simpson, E. L. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18327 · Cited by 25
Self-citationMastorino, L., Rosset, F., Gelato, F., Ortoncelli, M., Cavaliere, G., Quaglino, P., & Ribero, S. (2022) · Pharmaceuticals · doi:10.3390/ph15070883 · Cited by 25
Dodson, J. A., & Lio, P. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01047-w · Cited by 31
Mickevičius, T., Pink, A., Bhogal, M. S., O'Brart, D. P. S., & Robbie, S. J. (2022) · Cornea · doi:10.1097/ico.0000000000003162 · Cited by 28
Silverberg, J. I., Lynde, C. W., Abuabara, K., Patruno, C., Benedetto, A. D., Zhang, H., Thomas, R. B., Bégo-Le-Bagousse, G., Khokhar, F. A., Vakil, J., et al. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00754-4 · Cited by 29
Self-citationSystemic therapies in atopic dermatitis: The pipeline
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2017) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2017.03.012 · Cited by 29
Self-citationAtopic Dermatitis: Early Treatment in Children
Huang, A. H., Cho, C., Leung, D. Y. M., & Brar, K. (2017) · Current Treatment Options in Allergy · doi:10.1007/s40521-017-0140-6 · Cited by 32
Establishment of a Mouse Model of Atopic Dermatitis by Deleting Ikk2 in Dermal Fibroblasts
Nunomura, S., Ejiri, N., Kitajima, M., Nanri, Y., Arima, K., Mitamura, Y., Yoshihara, T., Fujii, K., Takao, K., Imura, J., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.047 · Cited by 32
Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis
Hendricks, A. J., Lio, P., & Shi, V. Y. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00436-8 · Cited by 25
Bosma, A. L., Spuls, P. I., García-Doval, I., Naldi, L., Prieto‐Merino, D., Tesch, F., Apfelbacher, C., Arents, B. W. M., Barbarot, S., Baselga, E., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18452 · Cited by 26
Self-citationSeborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports
Al‐Janabi, A., & Marsland, A. M. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2871 · Cited by 25
Targeting Mast Cells with Biologics
Lyons, J. J., & Metcalfe, D. D. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.007 · Cited by 28
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Calabrese, L., D’Onghia, M., Lazzeri, L., Rubegni, G., & Cinotti, É. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070775 · Cited by 29
“Despite being a truly significant milestone in AD management, only 35% to 40% of patients on dupilumab achieve clear or almost clear skin (IGA score 0/1), thus endorsing the need for additional treatment options [39].”
BackgroundBosticardo, M., Dobbs, K., Delmonte, O. M., Martins, A. J., Pala, F., Kawai, T., Kenney, H., Magro, G., Rosen, L. B., Yamazaki, Y., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adq1697 · Cited by 28
New and Emerging Biologics for Atopic Dermatitis
Baghoomian, W., Na, C. H., & Simpson, E. L. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00515-1 · Cited by 25
Self-citationBiologics for Atopic Dermatitis
Boguniewicz, M. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.004 · Cited by 24
Chronic Itch of Unknown Origin Is Associated With an Enhanced Th2 Skin Immune Profile
Dehner, C. A., Chen, L., Kim, B., & Rosman, I. S. (2021) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001902 · Cited by 25
The New Era of Biologics in Atopic Dermatitis: A Review
Schneider, S., Li, L., & Zink, A. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1104a144 · Cited by 28
“Adverse effects were mild to moderate and comprised nasopharyngitis, upper respiratory tract infections, conjunctivitis, injection-site reactions, and exacerbation of AD [11].”
BackgroundMethodStrober, B. E., Mallya, U. G., Yang, M., Ganguli, S., Gadkari, A. S., Wang, J. J. J., Sierka, D., Delevry, D., & Kimball, A. B. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.4778 · Cited by 25
Self-citationCutaneous neuroimmune crosstalk in pruritus
Agelopoulos, K., Pereira, M. P., Wiegmann, H., & Ständer, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.005 · Cited by 30
Thyssen, J. P., Thaçi, D., Bieber, T. R. M., Gooderham, M., de Bruin-Weller, M. S., Soong, W., Kabashima, K., Barbarot, S., Luna, P. C., Xu, J., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19232 · Cited by 25
Self-citationZhang, L., Ding, Y., Wang, Q., Pan, W., Wei, Z., Smith, P. A., & Yang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-39311-2 · Cited by 28
Biologics for severe asthma and beyond
Mümmler, C., & Milger, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108551 · Cited by 27
Paller, A. S., Pinter, A., Lee, L. W., Aschoff, R., Zdybski, J., Schnopp, C., Praestgaard, A. H., Bansal, A., Shumel, B. S., Prescilla, R. P., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02753-1 · Cited by 33
“Although cases of conjunctivitis and mollus-cum contagiosum were more frequent in the dupilumab group than in the placebo group, they were mild and resolved by the end of treatment.”
BackgroundEvolving Concepts in Atopic Dermatitis
Sidbury, R., & Khorsand, K. O. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0710-5 · Cited by 28
Changing perspectives in atopic dermatitis
Serra‐Baldrich, E., de Frutos, F. J. O., Jauregui, I., Hita, J. C. A., Silvestre, J. F., Herraez, L., Martin‐Santiago, A., Valero, A., & Sastre, J. (2017) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2017.07.002 · Cited by 28
Adult atopic dermatitis: new and emerging therapies
Napolitano, M., Marasca, C., Fabbrocini, G., & Patruno, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1507734 · Cited by 25
“In two phase III trials lasting 16 weeks (SOLO 1 and SOLO 2), a total of 1379 adult patients with moderate-to-severe AD were randomized to receive weekly or biweekly injections of 300 mg dupilumab after a 600 mg loading dose or placebo [83].”
BackgroundDhadwal, G., Albrecht, L. E., Gniadecki, R., Poulin, Y. P., Yeung, J., Hong, C.-H., & Gooderham, M. (2018) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475418805721 · Cited by 25
“clinical efficacy observed as early as 2 weeks and for as long as 52 weeks.(55,56) Furthermore, the concomitant use of TCS appears to further improve clinical outcomes and, importantly, reflects the practical management of AD in real-world practice.”
Self-citationTohda, Y., Nakamura, Y., Fujisawa, T., Ebisawa, M., Arima, K., Miyata, M., Takahashi, Y., Rice, M. S., Deniz, Y. M., Rowe, P., et al. (2020) · Allergology International · doi:10.1016/j.alit.2020.04.002 · Cited by 25
Self-citationKubanov, A. A., Namazova-Baranova, L. S., Khaitov, R. M., Ивановна, И. Н., Alekseeva, A. A., Ambarchian, E. Т., Artemyeva, S. I., Arshinskiy, M. I., Astafyeva, N. G., Vishneva, Е. A., et al. (2021) · Russian Journal of Allergy · doi:10.36691/rja1474 · Cited by 29
Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis
Li, M., Wang, J., Liu, Q., Liu, Y., Mi, W., Li, W., & Li, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541776 · Cited by 37
Kamata, M., Sun, D. I., & Paller, A. S. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.04.042 · Cited by 27
Ali, A. A., Seng, E. K., Alavi, A., & Lowes, M. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.065 · Cited by 23
30 Years of Biotherapeutics Development—What Have We Learned?
Ghilardi, N., Pappu, R., Arron, J. R., & Chan, A. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101619-031510 · Cited by 27
Iannone, M., Tonini, G., Janowska, A., Dini, V., & Romanelli, M. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1933929 · Cited by 25
Tyring, S. K., Rich, P. A., Tada, Y., Beeck, S., Messina, I., Liu, J., Huang, X., & Shumack, S. P. (2023) · Dermatology and Therapy · doi:10.1007/s13555-022-00876-x · Cited by 25
“The response rates were lower than what has been observed in other clinical trials in AD [16, 18].”
Wang, J., White, J., Sansone, K. J., Spelman, L. J., Sinclair, R. D., Yang, X., Pan, W., & Wei, Z. (2023) · Clinical and Translational Science · doi:10.1111/cts.13656 · Cited by 25
Real-life studies of biologics used in asthma patients: key differences and similarities to trials
Heffler, E. M., Paoletti, G., Giorgis, V. D., Puggioni, F., Racca, F., Giacco, S. D., Bagnasco, D., Caruso, C., Brussino, L., Rolla, G., et al. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1653758 · Cited by 26
“to 14% of patients compared to <1%-8% in the placebo cohorts in phase III trials [52,53] and real-life studies [54]), while it is an infrequent adverse event in dupilumab treated”
BackgroundBiologics in Children with Allergic Diseases
Licari, A., Manti, S., Marseglia, A., Filippo, M. D., Sando, E. D., Foiadelli, T., & Marseglia, G. L. (2019) · Current Pediatric Reviews · doi:10.2174/1573396315666191029123822 · Cited by 24
Nahm, D., Ye, Y., Shin, Y. S., Park, H., Kim, M., Kwon, B., Cho, S.-M., & Han, J. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.6.949 · Cited by 22
Bax, C. E., Khurana, M. C., Treat, J. R., Castelo‐Soccio, L. A., Rubin, A. I., & McMahon, P. J. (2021) · Pediatric Dermatology · doi:10.1111/pde.14499 · Cited by 23
Chovatiya, R., Ribero, S., Wollenberg, A., Park, C. O., Silvestre, J. F., Hong, H., Sénéschal, J., Saeki, H., Thyssen, J. P., Øland, C. B., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00931-1 · Cited by 30
Self-citationCutaneous Adverse Events Following Nemolizumab Administration: A Review
Mima, Y., Yamamoto, M., & Iozumi, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093026 · Cited by 23
“Dupilumab, an IL-4 receptor alpha (IL-4R α ) antagonist, was the first biologic approved for use in the treatment of AD and has demonstrated sustained efficacy in Phase III clinical trials [47,48].”
Advances in atopic dermatitis and urticarial in 2016
Honda, T., Nomura, T., & Kabashima, K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.005 · Cited by 25
Rademaker, M., Agnew, K., Andrews, M., Baker, C., Foley, P. A., Gebauer, K., Gupta, M., Rubel, D. M., Somerville, C., Sullivan, J. R., et al. (2019) · Australasian Journal of Dermatology · doi:10.1111/ajd.13141 · Cited by 25
Current treatments for atopic dermatitis in Japan
Miyano, K., & Tsunemi, Y. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15730 · Cited by 22
Kridin, K., Schonmann, Y., Solomon, A., Onn, E., Bitan, D. T., Weinstein, O., & Cohen, A. D. (2021) · Immunologic Research · doi:10.1007/s12026-021-09234-z · Cited by 22
Felfeli, T., Georgakopoulos, J. R., Jo, C. E., Mimouni, M., Piguet, V., Drucker, A. M., Yeung, J., & Chan, C. C. (2021) · Cornea · doi:10.1097/ico.0000000000002866 · Cited by 22
Blauvelt, A., de Bruin-Weller, M. S., Simpson, E. L., Chen, Z., Zhang, A., & Shumel, B. S. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00638-1 · Cited by 23
Self-citationWang, Y., Choy, C. T., Lin, Y., Wang, L., Hou, J., Tsui, J. C. C., Zhou, J., Wong, C. H., Yim, T. K., Tsui, W.-K., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112904 · Cited by 24
“EASI score could therefore range from 0 to 72 with higher score indicating worse severity [52].”
Hughes, C., Nathan, J., Mathew, L., Pink, A., Woolf, R., Smith, C. H., Menon, B. S., & Kirkham, B. W. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42558 · Cited by 22
Rothenberg‐Lausell, C., Bar, J., Dahabreh, D., Renert‐Yuval, Y., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.04.009 · Cited by 27
Self-citationCommon and different roles of IL-4 and IL-13 in skin allergy and clinical implications
Roesner, L. M., Zeitvogel, J., & Heratizadeh, A. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000553 · Cited by 25
Tralokinumab for the Treatment of Atopic Dermatitis
Freitas, E., Guttman‐Yassky, E., & Torres, T. R. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00613-8 · Cited by 23
Self-citationCutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1
Uluçkan, Ö., Jiménez, M., Roediger, B., Schnabl, J., Díez-Córdova, L. T., Troulé, K., Weninger, W., & Wagner, E. F. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.042 · Cited by 21
Bullous pemphigoid: A practical approach to diagnosis and management in the modern era
Powers, C. M., Thakker, S., Gulati, N., Talia, J., Dubin, D. P., Zone, J. J., Culton, D. A., Hopkins, Z. H., & Aðalsteinsson, J. A. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.01.086 · Cited by 26
Pala, V., Rosset, F., Mastorino, L., Sciamarrelli, N., Boskovic, S., Borriello, S., Bongiovanni, E., Crespi, O., Ribero, S., & Quaglino, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110720 · Cited by 25
“This therapeutic approach not only attenuates inflammation and pruritus but also promotes restoration of the epidermal barrier, reinforcing the upstream role of Th2 cytokines in disease pathophysiology [10].”
Morris, G. M., Nahmias, Z. P., & Kim, B. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.12.016 · Cited by 21
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 23
Current Perspectives on the Management of Infantile Atopic Dermatitis
Davari, D. R., Nieman, E. L., McShane, D. B., & Morrell, D. S. (2020) · Journal of Asthma and Allergy · doi:10.2147/jaa.s246175 · Cited by 26
Time to meaningful clinical response in reduction of itch in atopic dermatitis
Lin, D. H., Nguyen, C., & Fleischer, A. B. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1856318 · Cited by 21
Eczema is a shared risk factor for anxiety and depression: A meta-analysis and systematic review
Long, Q., Jin, H., Xu, Y., Liu, Y., Teng, Z., Chen, Y., Zhu, Y. K., & Zeng, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263334 · Cited by 26
Gael, M., Adam, T., Mariano‐Bourin, M., & Bursztejn, A. ‐. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18221 · Cited by 21
Roy, Y. R. L., Ficheux, A., Misery, L., & Brenaut, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1079323 · Cited by 28
“placebo (671 and 708 patients included, respectively) (45).”
Kishi, R., Toyama, S., Tominaga, M., Kamata, Y., Komiya, E., Kaneko, T., Suga, Y., & Takamori, K. (2023) · Cells · doi:10.3390/cells12020239 · Cited by 20
“The primary outcome, EASI-75, which is used in clinical phase 3 AD trials, was achieved by 44– 69% of patients after 16 weeks of treatment [10,11].”
BackgroundMethodDiscovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis
Thoma, G., Duthaler, R. O., Waelchli, R., Hauchard, A., Bruno, S., Strittmatter-Keller, U., Leon, A. C. O., Viebrock, S., Aichholz, R., Beltz, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01977 · Cited by 23
Lin, T., Wang, C.-Y., Wang, F., Kang, E. Y., & Hwang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041031 · Cited by 24
“…= 55) vs. Placebo QW (n = 54) for 12 weeks Adult 36.5 (11.69) 46.8%/53.2% 74.55% (41/55) 23.64% (13/55) dupilumab vs. 3.70% (2/54) placebo 28 weeks Simpson 2016 (NCT02277743) (NCT02277769) Atopic dermatitis Three-arm, triple-blind, placebo-controlled RCT Dupilumab 300mg QW (n = 223) vs. Dupilumab…”
InfluentialThe impact of dupilumab on skin barrier function: A systematic review
Montero‐Vílchez, T., la Torre, R. S.-D., Sánchez‐Díaz, M., Ureña‐Paniego, C., Molina‐Leyva, A., & Arias‐Santiago, S. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19081 · Cited by 26
Rand, K., Ramos-Goñi, J. M., Akmaz, B., Solé-Feu, L., & Hita, J. C. A. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01058-z · Cited by 25
“This is very similar to the reported findings for week 16 after administration of 300 mg dupilumab Q2W in the SOLO 1 and 2 trials, where 52.5% and 48.1% achieved EASI-75, respectively, and 37.2% and 36.4% achieved IGA 0/1 with at least a 2-point improvement, respectively [29].”
MethodResultInfluential
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.